1. Home
  2. KTTA vs RNTX Comparison

KTTA vs RNTX Comparison

Compare KTTA & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pasithea Therapeutics Corp.

KTTA

Pasithea Therapeutics Corp.

HOLD

Current Price

$0.86

Market Cap

18.9M

Sector

Health Care

ML Signal

HOLD

RNTX

Rein Therapeutics Inc.

HOLD

Current Price

$1.43

Market Cap

30.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KTTA
RNTX
Founded
2020
2001
Country
United States
United States
Employees
4
11
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
18.9M
30.0M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
KTTA
RNTX
Price
$0.86
$1.43
Analyst Decision
Strong Buy
Buy
Analyst Count
1
2
Target Price
$3.00
$10.00
AVG Volume (30 Days)
111.1K
82.3K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.28
$1.02
52 Week High
$2.34
$2.22

Technical Indicators

Market Signals
Indicator
KTTA
RNTX
Relative Strength Index (RSI) 57.65 67.89
Support Level $0.67 $1.34
Resistance Level $0.90 $1.57
Average True Range (ATR) 0.06 0.11
MACD 0.01 0.03
Stochastic Oscillator 94.76 86.84

Price Performance

Historical Comparison
KTTA
RNTX

About KTTA Pasithea Therapeutics Corp.

Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. Its pipeline includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module).

About RNTX Rein Therapeutics Inc.

Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.

Share on Social Networks: